Design Therapeutics, Inc.
DSGN
$14.83
$0.443.06%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 58.78M | 58.13M | 59.13M | 57.86M | 55.15M |
| Gross Profit | -58.78M | -58.13M | -59.13M | -57.86M | -55.15M |
| SG&A Expenses | 20.58M | 20.62M | 20.34M | 20.13M | 19.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 79.36M | 78.76M | 79.47M | 77.99M | 74.93M |
| Operating Income | -79.36M | -78.76M | -79.47M | -77.99M | -74.93M |
| Income Before Tax | -70.80M | -69.71M | -69.79M | -67.45M | -63.49M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -70.80 | -69.71 | -69.79 | -67.45 | -63.49 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -70.80M | -69.71M | -69.79M | -67.45M | -63.49M |
| EBIT | -79.36M | -78.76M | -79.47M | -77.99M | -74.93M |
| EBITDA | -78.74M | -78.14M | -78.85M | -77.38M | -74.31M |
| EPS Basic | -1.18 | -1.19 | -1.22 | -1.19 | -1.12 |
| Normalized Basic EPS | -0.74 | -0.75 | -0.76 | -0.74 | -0.70 |
| EPS Diluted | -1.18 | -1.19 | -1.22 | -1.19 | -1.12 |
| Normalized Diluted EPS | -0.74 | -0.75 | -0.76 | -0.74 | -0.70 |
| Average Basic Shares Outstanding | 239.63M | 233.98M | 229.30M | 227.25M | 226.92M |
| Average Diluted Shares Outstanding | 239.63M | 233.98M | 229.30M | 227.25M | 226.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |